Zhang, Liding
Cao, Kai
Xie, Jun
Liang, Xiaohan
Gong, Hui
Luo, Qingming
Luo, Haiming
Funding for this research was provided by:
National Funded Postdoctoral Researchers Program (GZC20230651)
the STI2030-Major Projects (2021ZD0201001, 2021ZD0201001)
National Natural Science Foundation of China (81971025)
Article History
Received: 6 December 2023
Accepted: 9 May 2024
First Online: 23 May 2024
Declarations
:
: All procedures involving experimental animals were carried out under guidelines approved by the Institutional Animal Care and Use Committee of Huazhong University of Science and Technology.
: Not applicable.
: The authors declare no competing interests.
: The online version contains supplementary material available at https://doi.Synthetic scheme of protein-modified bMSNs@Ce (Fig. ); The size and Zeta potential of Nanoparticles (Fig. ); XPS analysis of RVG29-bMSNs@Ce-1F12 (Fig. ); The AFM image of RVG29-bMSNs@Ce-1F12 (Fig. ); Characterization of RVG29-bMSNs@Ce-1F12 (Fig. ); Hydroxyl radical scavenging test (Fig. ); Biocompatibility assay (Fig. ); Characterization of Aβ plaque stained with 1F12 and RVG29-bMSNs@Ce (Fig. ); Evaluation of the ability of RVG29-bMSNs@Ce-1F12 to inhibit Aβ aggregation (Fig. ); RVG29-bMSNs@Ce-1F12 alleviates Aβ<sub>42</sub> aggregates-induced microgliosis (Fig. 0); Biodistribution of 1F12 and RVG29-bMSNs@Ce (Fig. 1); IP-Western blot analysis of Aβ<sub>42</sub> level in plasma of APP/PS1 mice after different treatments (Fig. 2); Soluble p-tau<sup>396,404</sup> levels in the brains of mice treated with RVG29-bMSNs@Ce-1F12, 1F12, RVG29-bMSNs@Ce, and saline were detected by dot blot (Fig. 3); RVG29-bMSNs@Ce-1F12 ameliorates learning and memory impairments in APP/PS1 mice (Fig. 4).